EDIL3 (EGF-like repeats and discoidin domains 3), also known as Del1 (developmental endothelial locus 1), is a secreted extracellular matrix protein implicated in angiogenesis, inflammation, and tissue repair. It is predominantly expressed during embryonic development and in endothelial cells, macrophages, or tumor-associated stromal cells under pathological conditions. Structurally, EDIL3 contains EGF-like repeats that mediate interactions with integrins (e.g., αvβ3 and αvβ5) and discoidin domains involved in cell adhesion. Functionally, EDIL3 modulates vascular remodeling by promoting endothelial cell migration and tube formation while suppressing excessive inflammation through inhibition of leukocyte adhesion. Its dysregulation is linked to diseases such as cancer, atherosclerosis, and ischemic injury.
EDIL3 antibodies are essential tools for detecting and quantifying EDIL3 protein expression in research settings. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and ELISA to study EDIL3's roles in vascular biology, tumor microenvironment modulation, and inflammatory responses. Some therapeutic studies explore EDIL3-neutralizing antibodies to inhibit angiogenesis in cancers or atherosclerosis, while others investigate recombinant EDIL3 or agonistic antibodies to enhance tissue repair in ischemic conditions. The specificity and reliability of EDIL3 antibodies depend on epitope selection, with validated clones targeting conserved regions across species. Ongoing research aims to clarify EDIL3's context-dependent roles and therapeutic potential in human diseases.